๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer

โœ Scribed by David Cunningham; Trevor J. Powles; Mitchell Dowsett; Gillian Hutchison; Angela M. H. Brodie; Hubert T. Ford; Jean-Claude Gazet; R. Charles Coombes

Publisher
Springer
Year
1987
Tongue
English
Weight
292 KB
Volume
20
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Antibodies to 4-hydroxyandrostenedione โ€”
Antibodies to 4-hydroxyandrostenedione โ€” a new anti-breast cancer agent suitable for use in a radioimmunoassay
โœ J. Khubieh; G. W. Aherne; J. Chakraborty ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› Springer ๐ŸŒ English โš– 160 KB

A specific antiserum suitable for radioimmunoassay (RIA) of 4-hydroxy-4-androstene-3,17 dione (4-OHA) has been developed. Sheep antiserum was raised by injecting two different conjugates prepared by coupling 4-OHA to ovalbumin. Antisera obtained from a sheep immunised with 4-hydroxy-testosterone-17-

Capecitabine, a new oral fluoropyrimidin
Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer
โœ Francesco Di Costanzo; Andrea Sdrobolini; Silvia Gasperoni ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 200 KB

Capecitabine (Xeloda) ยฎ was developed as a tumour-selective fluoropyrimidine carbamate to achieve higher intratumoural 5-FU level and lower toxicity than 5-FU. Capecitabine passes unchanged through the gastrointestinal tract and is metabolised in the liver to 5%-deoxy-5-fluorocytidine (5%-DFCR). Her